News - Zytiga, Xarelto

Filter

Current filters:

ZytigaXarelto

Popular Filters

1 to 25 of 103 results

Report: New drugs needed for prostate cancer as incidents rise

Report: New drugs needed for prostate cancer as incidents rise

21-03-2014

Over half a million cases of prostate cancer will be diagnosed worldwide in 2014 leading to a demand…

EuropeJohnson & JohnsonOncologyPharmaceuticalResearchUSAXtandiZytiga

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

14-02-2014

There was further negative news for Germany’s Bayer and partner US health care giant Johnson & Johnson,…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

FDA advisory panel nixes approval of J&J and Bayer’s Xarelto for wider use

FDA advisory panel nixes approval of J&J and Bayer’s Xarelto for wider use

17-01-2014

The US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted against…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

BTG reveals six-month revenue up 17% and meets analysts’ expectations

12-11-2013

UK specialist health care company BTG (LSE: BTG) has announced its interim results for the six months…

BTGEuropeFinancialLemtradaOncologyPharmaceuticalTheraSphereUKZytiga

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

AstraZeneca to co-promote Janssen prostate cancer drug in Japan

11-10-2013

Anglo-Swedish drug major AstraZeneca has entered into an agreement with US health care giant Johnson…

abirateroneAsia-PacificAstraZenecaJanssenJohnson & JohnsonLicensingMarkets & MarketingOncologyPharmaceuticalZytiga

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

22-09-2013

Data from the Phase III EINSTEIN clinical trial program published Friday in the Thrombosis Journal underline…

BayerCardio-vascularPharmaceuticalResearchXarelto

Prostate cancer market set to grow 50% by 2021: report

06-09-2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Bayer reports on anticoagulation reversal activity with PCCs in patients treated with Xarelto

02-07-2013

German pharma major Bayer (BAYN: DE) has today (July 2) revealed results of an open-label, single-center,…

BayerCardio-vascularPharmaceuticalResearchXarelto

Bayer's Xarelto gains EU clearance for secondary prevention after ACS

28-05-2013

German chemical and pharma group Bayer (BAYN: DE) says that its novel oral anticoagulant Xarelto (rivaroxaban)…

BayerCardio-vascularEuropeJohnson & JohnsonPharmaceuticalRegulationXarelto

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

IQWiG says some men with metastatic prostate cancer can benefit from J&J's Zytiga

29-04-2013

In an early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products…

EuropeJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Draft guidance from NICE recommends Bayer's Xarelto for PE and DVT

19-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) this morning (April 19)…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

1 to 25 of 103 results

Back to top